CD8A and chronic hepatitis B virus infection: Another phase IIb trial has indicated the benefits of pegylated IFN-III therapy in chronic hepatitis B patients by enhancing NK and CD8+ T cell response, which therefore impeded viral replication and antigen levels, while the treatment of IFN-I induced detrimental outcomes (129).